MICHAEL S NEWMAN, D.O.
Osteopathic Medicine at Zion Ave, San Diego, CA
License number
California 20A 12416
Category
Osteopathic Medicine
Type
Critical Care Medicine
License number
California 246136
Category
Osteopathic Medicine
Type
Critical Care Medicine
License number
California 20A 12416
Category
Osteopathic Medicine
Type
Pulmonary Disease
License number
California 246136
Category
Osteopathic Medicine
Type
Pulmonary Disease
License number
California OP60477657
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
4647 Zion Ave, San Diego, CA 92120
Phone
(619) 528-5865
(619) 528-3189 (Fax)
(619) 528-3189 (Fax)
Personal information
See more information about MICHAEL S NEWMAN at radaris.comName
Address
Phone
4914 Londonberry Dr, Santa Rosa, CA 95403
481 W Mesa Ave APT 11, Clovis, CA 93612
508 14Th St, Modesto, CA 95354
505 Sansome St STE 1500, San Francisco, CA 94111
5052 Via Serena, Rch Cucamonga, CA 91701
Professional information
National Account Manager
Position:
National Account Manager at CIGNA Healthcare
Location:
Greater San Diego Area
Industry:
Insurance
Work:
CIGNA Healthcare
since Jan 2002
-
National Account Manager
Education:
CCSN/UNLV 1998 - 2001
Independent Events Services Professional
Location:
Greater San Diego Area
Industry:
Events Services
Modulators Of Protein Tyrosine Phosphatases (Ptpases)
US Patent:
6613903, Sep 2, 2003
Filed:
Jul 9, 2001
Appl. No.:
09/901367
Inventors:
Henrik Sune Andersen - Lyngby, DK
Thomas Kruse Hansen - Herlev, DK
Jesper Lau - Farum, DK
Niels Peter Hundahl Moller - Kobenhavn O, DK
Ole Hvilsted Olsen - Bronshoj, DK
Frank Urban Axe - Escondido CA
Farid Bakir - San Diego CA
Yu Ge - San Diego CA
Daniel Dale Holsworth - San Diego CA
Luke Milburn Judge - Seattle WA
Michael James Newman - San Diego CA
Roy Teruyuki Uyeda - San Diego CA
Barry Zvi Shapira - Acton CA
Thomas Kruse Hansen - Herlev, DK
Jesper Lau - Farum, DK
Niels Peter Hundahl Moller - Kobenhavn O, DK
Ole Hvilsted Olsen - Bronshoj, DK
Frank Urban Axe - Escondido CA
Farid Bakir - San Diego CA
Yu Ge - San Diego CA
Daniel Dale Holsworth - San Diego CA
Luke Milburn Judge - Seattle WA
Michael James Newman - San Diego CA
Roy Teruyuki Uyeda - San Diego CA
Barry Zvi Shapira - Acton CA
Assignee:
Novo Nordisk A/S - Bagsvaerd
International Classification:
C07D47102
US Classification:
546114, 514301
Abstract:
The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) including PTP1B, T cell PTP, wherein X, R , R , R , and R are defined more fully in the description. The compounds are useful in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.
Therapeutic Compositions And Methods For Antibody And Fc-Containing Targeting Molecule-Based Targeted Delivery Of Bioactive Molecules By Bacterial Minicells
US Patent:
2012020, Aug 16, 2012
Filed:
Feb 15, 2012
Appl. No.:
13/397313
Inventors:
Matthew J. Giacalone - San Diego CA, US
Michael J. Newman - San Diego CA, US
Michael J. Newman - San Diego CA, US
Assignee:
Vaxiion Therapeutics, Inc. - San Diego CA
International Classification:
A61K 39/395, A61P 37/04
US Classification:
4241341
Abstract:
The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.
Modulators Of Protein Tyrosine Phosphatases (Ptpases)
US Patent:
2002009, Jul 25, 2002
Filed:
Jul 9, 2001
Appl. No.:
09/901284
Inventors:
Henrik Andersen - Lyngby, DK
Thomas Hansen - Herlev, DK
Jesper Lau - Farum, DK
Niels Moller - Kobenhavn O, DK
Ole Olsen - Bronshoj, DK
Frank Axe - Escondido CA, US
Farid Bakir - San Diego CA, US
Yu Ge - San Diego CA, US
Daniel Holsworth - San Diego CA, US
Luke Judge - Seattle WA, US
Michael Newman - San Diego CA, US
Roy Uyeda - San Diego CA, US
Barry Shapira - Acton CA, US
Thomas Hansen - Herlev, DK
Jesper Lau - Farum, DK
Niels Moller - Kobenhavn O, DK
Ole Olsen - Bronshoj, DK
Frank Axe - Escondido CA, US
Farid Bakir - San Diego CA, US
Yu Ge - San Diego CA, US
Daniel Holsworth - San Diego CA, US
Luke Judge - Seattle WA, US
Michael Newman - San Diego CA, US
Roy Uyeda - San Diego CA, US
Barry Shapira - Acton CA, US
International Classification:
C07D498/02, A61K031/4743
US Classification:
514/301000, 546/114000
Abstract:
The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP (TC-PTP),
wherein X, R, R, R, and Rare defined more fully in the description. The compounds are useful in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.
Therapeutic Formulations Based On Asiatic Acid And Selected Salts Thereof
US Patent:
2010033, Dec 30, 2010
Filed:
Jan 8, 2009
Appl. No.:
12/811477
Inventors:
Ying Liu - Shanghai, CN
Quanhai Liu - Shanghai, CN
Yan Qin - Shanghai, CN
Tong Wu - Shanghai, CN
Zhiru Xu - Shanghai, CN
Min-yu Liu - Shanghai, CN
Fei Li - Shanghai, CN
Yan Li - Shanghai, CN
Michael J. Newman - San Diego CA, US
Quanhai Liu - Shanghai, CN
Yan Qin - Shanghai, CN
Tong Wu - Shanghai, CN
Zhiru Xu - Shanghai, CN
Min-yu Liu - Shanghai, CN
Fei Li - Shanghai, CN
Yan Li - Shanghai, CN
Michael J. Newman - San Diego CA, US
International Classification:
A61K 31/19, C07C 62/32, C07C 233/00, C07C 69/74, C07H 13/02, A61P 11/00, A61P 3/10, A61P 1/00, A61P 17/06, A61P 19/02
US Classification:
514557, 562508, 564123, 560126, 536119
Abstract:
A highly pure asiaticoside and a pharmaceutical grade asiatic acid can be prepared, along with salts of asiatic acid, for use in formulating therapeutic compositions that are suitable for treating arthritis, psoriasis and other inflammatory diseases, as well as pulmonary fibrosis, diabetic nephropathy, and other fibrotic diseases.
Methods & Compositions For Enhancing Pharmaceutical Treatments
US Patent:
2007020, Aug 30, 2007
Filed:
Jan 25, 2007
Appl. No.:
11/627289
Inventors:
Michael Newman - San Diego CA, US
William Dixon - La Jolla CA, US
William Dixon - La Jolla CA, US
Assignee:
Taiji Biomedical, Inc. - Menlo Park CA
International Classification:
A61K 31/417
US Classification:
514400000
Abstract:
Improved methods are provided for therapeutic and/or preventative treatment to a mammal in which the mammal is protected against the toxicity of active pharmaceutical agents that (i) bind to or are substrates for P-gp, (ii) are taxane analogues, and/or (iii) are inhibitors of tubulin disassembly. Additionally provided are compositions and methods useful for treating cell proliferative disorders. Further provided are methods of increasing the bioavailability of therapeutic and/or preventative treatments in a mammal. Particular embodiments are directed to increasing such bioavailability across the blood-brain barrier.
Methods And Compositions For Enhancing Pharmaceutical Treatments
US Patent:
2002014, Oct 10, 2002
Filed:
Mar 20, 2002
Appl. No.:
10/104549
Inventors:
Michael Newman - San Diego CA, US
William Dixon - La Jolla CA, US
William Dixon - La Jolla CA, US
International Classification:
A61K031/5377, A61K031/454, A61K031/4178
US Classification:
514/235800, 514/254050, 514/326000, 514/396000, 514/397000, 514/400000
Abstract:
Improved methods are provided for therapeutic and/or preventative treatment to a mammal in which the mammal is protected against the toxicity of active pharmaceutical agents that (i) bind to or are substrates for P-gp, (ii) are taxane analogues, and/or (iii) are inhibitors of tubulin disassembly. Additionally provided are compositions and methods useful for treating cell proliferative disorders. Further provided are methods of increasing the bioavailability of therapeutic and/or preventative treatments in a mammal. Particular embodiments are directed to increasing such bioavailability across the blood-brain barrier.
Compositions And Methods For Increasing Drug Efficiency
US Patent:
2005018, Aug 25, 2005
Filed:
Sep 22, 2004
Appl. No.:
10/948707
Inventors:
Michael Newman - San Diego CA, US
Angelo Castellino - San Diego CA, US
Joel Desharnais - San Diego CA, US
Zijian Guo - San Diego CA, US
Qing Li - San Diego CA, US
Carlo Ballatore - San Diego CA, US
Chengzao Sun - San Diego CA, US
Angelo Castellino - San Diego CA, US
Joel Desharnais - San Diego CA, US
Zijian Guo - San Diego CA, US
Qing Li - San Diego CA, US
Carlo Ballatore - San Diego CA, US
Chengzao Sun - San Diego CA, US
International Classification:
A61K038/14, A61K038/08, C07K007/08
US Classification:
514008000, 514015000, 530322000, 530328000, 530329000
Abstract:
In one embodiment, provided herein are compositions and methods for increasing drug efficiency. In certain embodiments, the compositions contain conjugates having the formula:
D-L-S
wherein D is a drug moiety; L, which may or may not be present, is a non-releasing linker moiety; and S is a substrate for a protein or lipid kinase that is overexpressed, overactive or exhibits undesired activity in a target system.
Compositions And Methods For Increasing Drug Efficiency
US Patent:
2006023, Oct 19, 2006
Filed:
Mar 14, 2006
Appl. No.:
11/376695
Inventors:
Michael Newman - San Diego CA, US
Angelo Castellino - San Diego CA, US
Joel Desharnais - San Diego CA, US
Zijian Guo - San Diego CA, US
Qing Li - San Diego CA, US
Carlo Ballatore - San Diego CA, US
Chengzao Sun - San Diego CA, US
Angelo Castellino - San Diego CA, US
Joel Desharnais - San Diego CA, US
Zijian Guo - San Diego CA, US
Qing Li - San Diego CA, US
Carlo Ballatore - San Diego CA, US
Chengzao Sun - San Diego CA, US
International Classification:
A61K 38/17, A61K 38/16
US Classification:
514002000, 514008000, 530395000, 530409000
Abstract:
In one embodiment, provided herein are compositions and methods for increasing drug efficiency. In certain embodiments, the compositions contain conjugates having the formula:
D-L-S
wherein D is a drug moiety; L, which may or may not be present, is a non-releasing linker moiety; and S is a substrate for a protein or lipid kinase that is overexpressed, overactive or exhibits undesired activity in a target system.